ArticleMolecular genetics & genomic medicine2026
Mosaicism for Cohen-Gibson Syndrome in a Female Individual With Overgrowth and Neurodevelopmental Delay.
Article in Molecular genetics & genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe Embryonic Ectoderm Development (EED) gene encodes a core component of the Polycomb Repressive Complex 2 (PRC2), which regulates chromatin structure and plays a key role in embryonic development and cell differentiation. Pathogenic variants in EED are associated with overgrowth-intellectual disability syndrome (Cohen-Gibson syndrome, OMIM #617561), though reported cases are rare and typically involve heterozygous germline variants. This study presents an individual with confirmed postzygotic mosaicism in EED, contributing to diagnostic complexity.
methodsA 12-year-old girl with tall stature, dysmorphic features, developmental delay, and congenital anomalies underwent clinical and genetic evaluation. Exome sequencing and targeted deep sequencing were used to identify and validate the genetic variant across multiple tissues.
resultsA likely pathogenic mosaic EED variant c.1091G > T; p.(Trp364Leu) was identified in the patient with a 31% variant allele fraction in peripheral blood. Deep sequencing confirmed the variant and its de novo origin in the parents' samples. Mosaicism was also detected in two independently collected buccal mucosa samples (dry swab and buccal swab collection kit; 11% and 17%) and in saliva (30%), indicating somatic mosaicism in multiple tissues. DNA methylation profiling revealed a high-confidence epigenetic signature consistent with a PRC2 complex-associated disorder, further supporting the likely pathogenic classification of the identified variant.
conclusionThis case broadens the molecular understanding of EED-related disorders and highlights the clinical significance of mosaicism. Deep sequencing and multi-tissue analysis are crucial for accurate diagnosis, management, and genetic counseling in overgrowth syndromes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.